25.55
price up icon1.91%   0.48
 
loading
Precedente Chiudi:
$25.07
Aprire:
$24.85
Volume 24 ore:
546.86K
Relative Volume:
1.14
Capitalizzazione di mercato:
$828.60M
Reddito:
$154.15M
Utile/perdita netta:
$-33.58M
Rapporto P/E:
-26.61
EPS:
-0.96
Flusso di cassa netto:
$-20.74M
1 W Prestazione:
+6.50%
1M Prestazione:
-11.68%
6M Prestazione:
-49.51%
1 anno Prestazione:
+155.50%
Intervallo 1D:
Value
$24.09
$25.58
Intervallo di 1 settimana:
Value
$22.83
$25.58
Portata 52W:
Value
$10.04
$59.23

Harrow Inc Stock (HROW) Company Profile

Name
Nome
Harrow Inc
Name
Telefono
615.733.4731
Name
Indirizzo
102 WOODMONT BLVD, NASHVILLE, CA
Name
Dipendente
382
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-17
Name
Ultimi documenti SEC
Name
HROW's Discussions on Twitter

Confronta HROW con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
HROW
Harrow Inc
25.55 828.60M 154.15M -33.58M -20.74M -0.96
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
153.47 65.50B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.03 46.99B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.18 45.96B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
14.87 17.04B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
291.38 12.77B 2.76B 1.11B 898.10M 22.77

Harrow Inc Stock (HROW) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-06 Iniziato H.C. Wainwright Buy
2024-12-04 Reiterato B. Riley Securities Buy
2024-04-11 Iniziato Craig Hallum Buy
2022-09-08 Ripresa B. Riley Securities Buy
2021-10-14 Ripresa B. Riley Securities Buy
2021-09-24 Iniziato Aegis Capital Buy
2021-07-02 Iniziato Ladenburg Thalmann Buy
Mostra tutto

Harrow Inc Borsa (HROW) Ultime notizie

pulisher
Apr 24, 2025

Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic L - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic Launch - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - Seeking Alpha

Apr 24, 2025
pulisher
Apr 24, 2025

Harrow Authorizes Nordic Group Unit to sell Generic Version of Maxitrol eye Treatment - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - Morningstar

Apr 24, 2025
pulisher
Apr 21, 2025

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance

Apr 21, 2025
pulisher
Apr 21, 2025

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives Propel Success - GuruFocus

Apr 21, 2025
pulisher
Apr 10, 2025

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Business Wire

Apr 10, 2025
pulisher
Apr 01, 2025

Where Harrow Stands With AnalystsHarrow (NASDAQ:HROW) - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

B. Riley Adjusts Price Target on Harrow to $65 From $69, Maintains Buy Rating - MarketScreener

Apr 01, 2025
pulisher
Mar 31, 2025

H.C. Wainwright maintains $57 target on Harrow Health stock - Investing.com

Mar 31, 2025
pulisher
Mar 29, 2025

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives By GuruFocus - Investing.com Canada

Mar 29, 2025
pulisher
Mar 29, 2025

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha

Mar 29, 2025
pulisher
Mar 29, 2025

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

Harrow Health Reports Strong 2024 Financial Performance - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Harrow Health (HROW) Gets a Buy from Craig-Hallum - The Globe and Mail

Mar 28, 2025
pulisher
Mar 27, 2025

Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Harrow: Q4 Earnings Snapshot - The Advocate

Mar 27, 2025
pulisher
Mar 27, 2025

Harrow Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Joplin Globe

Mar 27, 2025
pulisher
Mar 27, 2025

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 - Business Wire

Mar 27, 2025
pulisher
Mar 27, 2025

Harrow Health (HROW) Surpasses Q4 Earnings and Revenue Expectati - GuruFocus

Mar 27, 2025
pulisher
Mar 26, 2025

Harrow Inc. sees $150k stock sale by Opaleye Management - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Harrow Inc (HROW) Shares Gap Down to $27.235 on Mar 26 - GuruFocus

Mar 26, 2025
pulisher
Mar 24, 2025

Harrow sees shares increase following drug approval - Nashville Post

Mar 24, 2025
pulisher
Mar 24, 2025

Craig-Hallum Reaffirms Their Buy Rating on Harrow Health (HROW) - The Globe and Mail

Mar 24, 2025
pulisher
Mar 24, 2025

CMS approves separate reimbursement for Harrow’s TRIESENCE - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire

Mar 24, 2025
pulisher
Mar 24, 2025

TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan

Mar 24, 2025
pulisher
Mar 22, 2025

Harrow Inc (HROW) Shares Up 1.14% on Mar 22 - GuruFocus

Mar 22, 2025
pulisher
Mar 22, 2025

Opaleye management sells $148,200 in Harrow, Inc. stock - Investing.com India

Mar 22, 2025
pulisher
Mar 21, 2025

What To Expect From Harrow Inc (HROW) Q4 2024 Earnings - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Opaleye Management Inc. Adjusts Stake in Harrow Inc. - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Bank of New York Mellon Corp Has $2.90 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Harrow Inc (HROW) Shares Up 2.97% on Mar 21 - GuruFocus

Mar 21, 2025
pulisher
Mar 20, 2025

Opaleye management sells $148,200 in Harrow, Inc. stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 19, 2025

Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial - GlobeNewswire Inc.

Mar 19, 2025
pulisher
Mar 18, 2025

Harrow stock surges on preliminary Q4 numbers - Nashville Post

Mar 18, 2025
pulisher
Mar 18, 2025

Sector Update: Health Care -March 18, 2025 at 08:49 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews

Mar 18, 2025
pulisher
Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga India

Mar 18, 2025
pulisher
Mar 18, 2025

Harrow Reports Preliminary 2024 Q4 and Full-Year Financial Results, Provides 2025 Guidance and Launches New Initiative - VisionMonday.com

Mar 18, 2025
pulisher
Mar 17, 2025

Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus.com

Mar 17, 2025

Harrow Inc Azioni (HROW) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$9.46
price up icon 0.00%
$27.84
price up icon 0.61%
$101.77
price down icon 1.80%
$8.13
price up icon 1.25%
$106.73
price up icon 0.92%
$291.38
price down icon 1.70%
Capitalizzazione:     |  Volume (24 ore):